Literature DB >> 21262078

Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis.

Graham Mowatt1, James N'Dow, Luke Vale, Ghulam Nabi, Charles Boachie, Jonathan A Cook, Cynthia Fraser, T R Leyshon Griffiths.   

Abstract

OBJECTIVES: The aim of this study was to assess the test performance and clinical effectiveness of photodynamic diagnosis (PDD) compared with white light cystoscopy (WLC) in people suspected of new or recurrent bladder cancer.
METHODS: A systematic review was conducted of randomized controlled trials (RCTs), nonrandomized comparative studies, or diagnostic cross-sectional studies comparing PDD with WLC. Fifteen electronic databases and Web sites were searched (last searches April 2008). For clinical effectiveness, only RCTs were considered.
RESULTS: Twenty-seven studies (2,949 participants) assessed test performance. PDD had higher sensitivity than WLC (92 percent, 95 percent confidence interval [CI], 80-100 percent versus 71 percent, 95 percent CI, 49-93 percent) but lower specificity (57 percent, 95 percent CI, 36-79 percent versus 72 percent, 95 percent CI, 47-96 percent). For detecting higher risk tumors, median range sensitivity of PDD (89 percent [6-100 percent]) was higher than WLC (56 percent [0-100 percent]) whereas for lower risk tumors it was broadly similar (92 percent [20-95 percent] versus 95 percent [8-100 percent]). Four RCTs (709 participants) using 5-aminolaevulinic acid (5-ALA) as the photosensitising agent reported clinical effectiveness. Using PDD at transurethral resection of bladder tumor (TURBT) resulted in fewer residual tumors at check cystoscopy (relative risk [RR], 0.37, 95 percent CI, 0.20-0.69) and longer recurrence-free survival (RR, 1.37, 95 percent CI, 1.18-1.59), compared with WLC.
CONCLUSIONS: PDD detects more bladder tumors than WLC, including more high-risk tumors. Based on four RCTs reporting clinical effectiveness, 5-aminolaevulinic acid-mediated PDD at TURBT facilitates a more complete resection and prolongs recurrence-free survival.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21262078     DOI: 10.1017/S0266462310001364

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  48 in total

1.  [Endourological imaging with narrow band imaging].

Authors:  C Doehn
Journal:  Urologe A       Date:  2012-06       Impact factor: 0.639

2.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

3.  The impact of completeness of last transurethral resection of bladder tumors on the outcomes of radical cystectomy.

Authors:  Stefania Zamboni; Marco Moschini; Andrea Gallina; Renzo Colombo; Francesco Montorsi; Alberto Briganti; Andrea Salonia; Alessandro Antonelli; Claudio Simeone; Sandra Belotti; Luca Cristinelli; Agostino Mattei; Philipp Baumeister
Journal:  World J Urol       Date:  2019-03-25       Impact factor: 4.226

Review 4.  [Photodynamic diagnostics of the bladder: current study results].

Authors:  A Karl; C Stief; D Zaak
Journal:  Urologe A       Date:  2013-04       Impact factor: 0.639

5.  [Differential diagnosis of hematuria].

Authors:  M Horstmann; T Franiel; M O Grimm
Journal:  Urologe A       Date:  2014-08       Impact factor: 0.639

6.  Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer.

Authors:  Alexander I Rolevich; Alexander G Zhegalik; Andrey A Mokhort; Alexander A Minich; Vladimir Yu Vasilevich; Sergey L Polyakov; Sergey A Krasny; Oleg G Sukonko
Journal:  World J Urol       Date:  2016-09-07       Impact factor: 4.226

7.  Narrow-band imaging assisted cystoscopy in the follow-up of patients with transitional cell carcinoma of the bladder: a randomized study in comparison with white light cystoscopy.

Authors:  S Tschirdewahn; N N Harke; L Hirner; E Stagge; B Hadaschik; Andreas Eisenhardt
Journal:  World J Urol       Date:  2019-08-30       Impact factor: 4.226

Review 8.  [Systemic treatment of bladder cancer].

Authors:  M Haas; M Burger; M J Schnabel
Journal:  Urologe A       Date:  2021-05-27       Impact factor: 0.639

Review 9.  [Supplementary optical techniques for the detection of nonmuscle invasive bladder cancer].

Authors:  S Aeishen; Y Dawood; S Papadoukakis; M Horstmann
Journal:  Urologe A       Date:  2018-02       Impact factor: 0.639

10.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.